What is StemCyte?
StemCyte operates as a leading cord blood bank, providing essential services for the storage of newborn stem cells. Trusted by a network of OBGYN and transplant physicians, the company offers both private and public banking options, empowering families to preserve their child's cord blood for potential future medical treatments. StemCyte is distinguished by its extensive and ethnically diverse stem cell inventory, actively participating in numerous clinical trials and achieving notable transplant success rates. The company's core mission is to offer parents assurance regarding their children's future health and access to treatments for a range of diseases.
How much funding has StemCyte raised?
StemCyte has raised a total of $2M across 2 funding rounds:
Debt
$1M
Debt
$963K
Debt (2020): $1M with participation from PPP
Debt (2021): $963K led by PPP
What's next for StemCyte?
With the recent major strategic investment, StemCyte is poised for accelerated expansion and innovation in the stem cell storage market. This capital injection is expected to bolster the company's research and development initiatives, potentially leading to advancements in transplant therapies and broader applications of stored stem cells. The company's focus on maintaining a diverse inventory and its established track record in clinical trials suggest a strategic direction towards solidifying its leadership in regenerative medicine and enhancing its capacity to serve a growing global demand for life-saving treatments.
See full StemCyte company page
